Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06252675 · ClinicalTrials.gov registry record · Phase 2

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

A Phase 2 study of Mantle Cell Lymphoma, sponsored by University of California, San Francisco.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
2
Study locations

NCT06252675 is a Phase 2 study of Mantle Cell Lymphoma that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06252675, a Phase 2 study of Mantle Cell Lymphoma, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Obinutuzumab may also reduce the risk of immune-related conditions from treatment. Pirtobrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the protein that signals cancer cells to multiply. Giving glofitamab in combination with pirtobrutinib may be safe, tolerable and/or effective in treating patients with relapsed or refractory mantle cell lymphoma.

Conditions Studied

Mantle Cell Lymphoma

Interventions

  • PROCEDURE Biospecimen Collection
  • DRUG Pirtobrutinib
  • BIOLOGICAL Obinutuzumab
  • BIOLOGICAL Glofitamab
  • PROCEDURE Tumor Imaging

Study Locations (2)

California

  • University of California, Davis - Davis
  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-06-11
Est. Completion 2028-07-31
Phase Phase 2

Sponsor

University of California, San Francisco

1,713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06252675

The ClinicalTrials.gov registry entry for NCT06252675 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (71% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06252675 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06252675 about?

NCT06252675 is a clinical study titled "Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma". This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Glofitamab and obinutu...

What is the current status of trial NCT06252675?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-06-11. Estimated completion is 2028-07-31.

What conditions does trial NCT06252675 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma.

What interventions are being tested in trial NCT06252675?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Pirtobrutinib (DRUG), Obinutuzumab (BIOLOGICAL), Glofitamab (BIOLOGICAL), Tumor Imaging (PROCEDURE).

Who is sponsoring clinical trial NCT06252675?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06252675 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mantle Cell Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.